3/19
10:44 am
srpt
Sarepta Therapeutics (SRPT) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $37.00 price target on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $37.00 price target on the stock.
3/19
10:34 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
3/19
10:34 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
3/13
09:46 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
3/13
09:46 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
3/10
10:52 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
3/10
10:52 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
3/2
08:03 am
srpt
Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
2/27
12:51 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
2/27
12:51 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
1/28
08:03 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $20.00 price target on the stock.
Medium
Report
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $20.00 price target on the stock.
1/27
08:04 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
1/23
08:58 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
1/23
08:58 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
1/14
08:04 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.